ECSP23070234A - Anti-cd30l antibodies and uses thereof - Google Patents

Anti-cd30l antibodies and uses thereof

Info

Publication number
ECSP23070234A
ECSP23070234A ECSENADI202370234A ECDI202370234A ECSP23070234A EC SP23070234 A ECSP23070234 A EC SP23070234A EC SENADI202370234 A ECSENADI202370234 A EC SENADI202370234A EC DI202370234 A ECDI202370234 A EC DI202370234A EC SP23070234 A ECSP23070234 A EC SP23070234A
Authority
EC
Ecuador
Prior art keywords
cd30l antibodies
cd30l
antibodies
ibd
disorders
Prior art date
Application number
ECSENADI202370234A
Other languages
English (en)
Inventor
Johan Fransson
Olivier Laurent
Burton Barnett
Mark Renshaw
Jessie-Farah Fecteau
Original Assignee
Dr Falk Pharma Gmbh
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh, Prometheus Biosciences Inc filed Critical Dr Falk Pharma Gmbh
Publication of ECSP23070234A publication Critical patent/ECSP23070234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen anticuerpos anti-CD30L y composiciones farmacéuticas para el tratamiento de enfermedades y trastornos autoinmunitarios tales como la enteropatía inflamatoria (IBD), incluida la enfermedad de Crohn (CD) y la colitis ulcerosa (UC).
ECSENADI202370234A 2021-02-17 2023-09-14 Anti-cd30l antibodies and uses thereof ECSP23070234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17

Publications (1)

Publication Number Publication Date
ECSP23070234A true ECSP23070234A (es) 2023-10-31

Family

ID=82931610

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202370234A ECSP23070234A (es) 2021-02-17 2023-09-14 Anti-cd30l antibodies and uses thereof

Country Status (20)

Country Link
US (3) US20240254246A1 (es)
EP (1) EP4294840A4 (es)
JP (2) JP7559257B2 (es)
KR (1) KR20230157356A (es)
CN (2) CN118047872A (es)
AR (1) AR124895A1 (es)
AU (1) AU2022224561A1 (es)
BR (1) BR112023016445A2 (es)
CA (1) CA3208060A1 (es)
CL (1) CL2023002393A1 (es)
CO (1) CO2023011962A2 (es)
CR (1) CR20230445A (es)
EC (1) ECSP23070234A (es)
GE (3) GEP20257791B (es)
IL (1) IL305146A (es)
JO (1) JOP20230186A1 (es)
MX (1) MX2023009621A (es)
PE (1) PE20231680A1 (es)
TW (1) TW202302637A (es)
WO (1) WO2022177963A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
EP4294840A4 (en) * 2021-02-17 2025-06-11 Prometheus Biosciences, Inc. ANTI-CD30L ANTIBODIES AND USES THEREOF
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
AR133766A1 (es) * 2023-09-12 2025-10-29 Amgen Inc Anticuerpos anti-cd30l y usos de los mismos
WO2025075049A1 (ja) * 2023-10-03 2025-04-10 国立大学法人京都大学 ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
CA2131003A1 (en) * 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2428321T3 (es) 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
JP2015502740A (ja) * 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
KR20180137614A (ko) * 2012-04-27 2018-12-27 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
EP2945865B1 (en) 2013-01-18 2019-01-09 LORD Corporation Active vibration control devices, systems, and methods
US10358497B2 (en) * 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
HRP20231367T1 (hr) * 2018-04-30 2024-02-16 Cedars-Sinai Medical Center Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
EP4294840A4 (en) 2021-02-17 2025-06-11 Prometheus Biosciences, Inc. ANTI-CD30L ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
EP4294840A1 (en) 2023-12-27
IL305146A (en) 2023-10-01
GEAP202516710A (en) 2025-05-13
JP2025004013A (ja) 2025-01-14
JOP20230186A1 (ar) 2023-08-09
TW202302637A (zh) 2023-01-16
GEAP202416351A (en) 2024-02-12
AR124895A1 (es) 2023-05-17
US11866505B2 (en) 2024-01-09
AU2022224561A1 (en) 2023-09-28
MX2023009621A (es) 2023-10-31
EP4294840A4 (en) 2025-06-11
PE20231680A1 (es) 2023-10-19
CL2023002393A1 (es) 2024-03-22
CN118047872A (zh) 2024-05-17
US12516126B2 (en) 2026-01-06
KR20230157356A (ko) 2023-11-16
JP7559257B2 (ja) 2024-10-01
GEP20257791B (en) 2025-09-10
US20240092923A1 (en) 2024-03-21
AU2022224561A9 (en) 2023-10-05
CN117255802A (zh) 2023-12-19
CO2023011962A2 (es) 2023-09-29
US20240254246A1 (en) 2024-08-01
CR20230445A (es) 2023-11-14
WO2022177963A1 (en) 2022-08-25
US20230060624A1 (en) 2023-03-02
JP2024509746A (ja) 2024-03-05
CA3208060A1 (en) 2022-08-25
BR112023016445A2 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
ECSP23070234A (es) Anti-cd30l antibodies and uses thereof
ECSP23070237A (es) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
ZA202204557B (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
ECSP15038626A (es) A61k 30/395
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
WO2019209995A3 (en) Optimized anti-tl1a antibodies
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CL2022001016A1 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
MX2020007917A (es) Derivados de tiofeno no condensados y sus usos.
CO2020005200A2 (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
MX2019012051A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
EA201790282A1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофил-эластазы
MX394066B (es) Nuevos compuestos
MX2023013083A (es) Compuestos y usos de los mismos.
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
MX2025001038A (es) Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos
BR112014029013A2 (pt) anticorpos de anti-ccl2 para tratamento de esclerodermia